BioSpecifics Technologies Corp (NASDAQ:BSTC) had its target price trimmed by from $72.00 to $65.00 in a report issued on Wednesday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Other equities analysts have also issued research reports about the stock. HC Wainwright set a $72.00 price target on shares of BioSpecifics Technologies Corp and gave the stock a buy rating in a research report on Thursday, August 10th. Zacks Investment Research raised shares of BioSpecifics Technologies Corp from a sell rating to a hold rating in a research report on Tuesday, October 10th. Finally, BidaskClub lowered shares of BioSpecifics Technologies Corp from a hold rating to a sell rating in a research report on Wednesday, August 2nd.

Shares of BioSpecifics Technologies Corp (NASDAQ:BSTC) traded down $0.94 during mid-day trading on Wednesday, reaching $43.18. 11,415 shares of the company traded hands, compared to its average volume of 19,647. BioSpecifics Technologies Corp has a 1 year low of $41.95 and a 1 year high of $58.79. The firm has a market capitalization of $309.35, a price-to-earnings ratio of 27.35 and a beta of 1.64.

BioSpecifics Technologies Corp (NASDAQ:BSTC) last issued its quarterly earnings results on Friday, November 10th. The biopharmaceutical company reported $0.37 EPS for the quarter, topping the consensus estimate of $0.36 by $0.01. BioSpecifics Technologies Corp had a net margin of 42.40% and a return on equity of 19.11%. The firm had revenue of $6.52 million during the quarter, compared to analyst estimates of $6.59 million. sell-side analysts forecast that BioSpecifics Technologies Corp will post 1.57 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “BioSpecifics Technologies Corp (BSTC) PT Lowered to $65.00 at” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark laws. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/11/18/biospecifics-technologies-corp-bstc-pt-lowered-to-65-00-at.html.

Several institutional investors have recently added to or reduced their stakes in BSTC. Bank of America Corp DE increased its position in shares of BioSpecifics Technologies Corp by 122.6% in the first quarter. Bank of America Corp DE now owns 2,489 shares of the biopharmaceutical company’s stock worth $137,000 after acquiring an additional 1,371 shares in the last quarter. US Bancorp DE increased its position in shares of BioSpecifics Technologies Corp by 1.1% in the second quarter. US Bancorp DE now owns 3,455 shares of the biopharmaceutical company’s stock worth $171,000 after acquiring an additional 36 shares in the last quarter. American International Group Inc. increased its position in shares of BioSpecifics Technologies Corp by 7.1% in the first quarter. American International Group Inc. now owns 3,327 shares of the biopharmaceutical company’s stock worth $182,000 after acquiring an additional 222 shares in the last quarter. Public Employees Retirement System of Ohio increased its position in shares of BioSpecifics Technologies Corp by 16.2% in the first quarter. Public Employees Retirement System of Ohio now owns 3,674 shares of the biopharmaceutical company’s stock worth $201,000 after acquiring an additional 513 shares in the last quarter. Finally, CAPROCK Group Inc. acquired a new stake in shares of BioSpecifics Technologies Corp in the second quarter worth $206,000. 53.92% of the stock is owned by institutional investors.

About BioSpecifics Technologies Corp

BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development.

Receive News & Stock Ratings for BioSpecifics Technologies Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies Corp and related stocks with our FREE daily email newsletter.